“With confidence he attributes to his free-range childhood, Chris Gibson has followed his instincts and his heart, stepping away from the MD/PhD program in which he’s enrolled to co-found and lead Recursion Pharmaceuticals, one of the buzziest companies bringing AI to drug development. In mid-July, Recursion closed a $121M Series C, bringing their valuation ever closer to unicorn status.”